Actinium Pharmaceuticals Inc (ATNM)
7.80
+0.10
(+1.30%)
USD |
NYAM |
May 01, 16:00
7.80
0.00 (0.00%)
After-Hours: 20:00
Actinium Pharmaceuticals Research and Development Expense (Quarterly): 8.118M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.118M |
| September 30, 2023 | 11.62M |
| June 30, 2023 | 11.08M |
| March 31, 2023 | 7.849M |
| December 31, 2022 | 7.333M |
| September 30, 2022 | 6.771M |
| June 30, 2022 | 4.662M |
| March 31, 2022 | 4.369M |
| December 31, 2021 | 5.416M |
| September 30, 2021 | 4.708M |
| June 30, 2021 | 3.631M |
| March 31, 2021 | 4.276M |
| December 31, 2020 | 4.639M |
| September 30, 2020 | 3.788M |
| June 30, 2020 | 3.508M |
| March 31, 2020 | 4.151M |
| December 31, 2019 | 3.374M |
| September 30, 2019 | 4.83M |
| June 30, 2019 | 4.01M |
| March 31, 2019 | 4.336M |
| December 31, 2018 | 5.072M |
| September 30, 2018 | 4.227M |
| June 30, 2018 | 3.330M |
| March 31, 2018 | 4.466M |
| Date | Value |
|---|---|
| December 31, 2017 | 3.672M |
| September 30, 2017 | 5.027M |
| June 30, 2017 | 4.448M |
| March 31, 2017 | 4.574M |
| December 31, 2016 | 4.229M |
| September 30, 2016 | 5.686M |
| June 30, 2016 | 4.148M |
| March 31, 2016 | 3.766M |
| December 31, 2015 | 2.787M |
| September 30, 2015 | 2.828M |
| June 30, 2015 | 3.838M |
| March 31, 2015 | 4.049M |
| December 31, 2014 | 4.406M |
| September 30, 2014 | 4.141M |
| June 30, 2014 | 2.131M |
| March 31, 2014 | 1.590M |
| December 31, 2013 | 0.7361M |
| September 30, 2013 | 0.7782M |
| June 30, 2013 | 0.5093M |
| March 31, 2013 | 1.086M |
| December 31, 2012 | 0.717M |
| September 30, 2012 | 1.677M |
| June 30, 2012 | 0.6013M |
| March 31, 2012 | 0.4449M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.374M
Minimum
Dec 2019
11.62M
Maximum
Sep 2023
5.691M
Average
4.662M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.08M |
| Eli Lilly and Co | 2.563B |
| Cellectar Biosciences Inc | 7.936M |
| Outlook Therapeutics Inc | 4.529M |
| Bristol-Myers Squibb Co | 2.695B |